Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal

Published

on

For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is ending that holdout with the proposed $1.5 billion deal for Myricx.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss

Published

on

The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.

Continue Reading

Uncategorized

BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine

Published

on

Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.

Continue Reading

Uncategorized

J&J pharma leader to retire; Krystal slumps on gene therapy miss

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

Read More

Published

on

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

Read More

Continue Reading
Advertisement

Trending